



MEDICAMEN BIOTECH LIMITED

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019

CIN : L74899DL 1993PLC056594

E-mail : cs@medicamen.com, www.medicamen.com

Un-audited Standalone and Consolidated Financial Results for the Quarter ended as on 30th June '2023

PART I	Particulars	Rupees in Lacs (Except per Share Data)					
		Standalone			Consolidated		
		Three Month period Ended		Year Ended	Three Month period Ended		Year Ended
		30.06.2023	31.03.2023	30.06.2022	31.03.2023	30.06.2022	31.03.2023
		Un-audited	Audited	Un-audited	Audited	Un-audited	Audited
1	Income from operations						
	(a) Net Sales / Income from operations	4,050.34	3,714.83	3,308.80	4,194.31	3,308.80	14,086.74
	(b) Other Income	37.92	34.65	96.23	37.92	96.23	246.22
	(c) Total Revenue	4,088.26	3,749.48	3,405.03	4,232.23	3,405.03	14,332.96
2	Expenses						
	a) Cost of Material Consumed	2,581.84	2,247.98	1,690.39	2,215.94	1,690.39	8,180.29
	b) Purchase of Goods Traded	-	-	-	-	-	-
	c) Changes in inventory of Finished Goods and Work in Progress	(524.06)	(109.86)	(0.93)	(524.14)	(0.93)	(970.95)
	d) Employees Benefits Expenses	524.65	437.94	434.18	656.39	434.18	2,044.38
	e) Finance Cost	95.65	85.76	76.72	95.65	76.72	292.27
	f) Depreciation and Amortisation Expenses	167.97	160.97	152.72	169.08	152.72	636.66
	g) Other expenses	726.88	462.00	619.45	756.07	619.45	2,445.82
	Total Expenses	3,572.93	3,284.79	2,972.53	3,763.90	2,972.53	12,628.46
3	Profit/(Loss) before Exceptional Items & Tax (1 - 2)	515.33	464.70	432.50	468.33	432.50	1,704.50
4	Exceptional Items (Commercial Tax Expenses Related to Earlier Years)	-	-	-	-	-	-
5	Profit/(Loss) before Extra Ordinary Items & Tax (3 - 4)	515.33	464.70	432.50	468.33	432.50	1,704.50
6	Tax Expenses						
	Current Year	124.62	107.50	97.88	124.62	97.88	369.96
	MAT Credit Entitlement	-	-	(23.93)	(136.88)	-	(138.31)
	Deferred Tax Liability	(50.99)	(47.40)	73.94	(50.99)	(23.93)	231.65
	Total Tax Expense	73.63	60.10	73.94	73.63	73.94	231.65
7	Net Profit /Loss for the period from Continuing operation (5- 6)	441.70	404.60	358.56	394.70	358.56	1,472.85




R. B. J...

8	Other Comprehensive Income Item that will not reclassified to Profit & Loss											
9	Total Comprehensive Income net of Tax	441.70	404.60	358.56	1,500.20	394.70	376.87	358.56	-	1,472.85		
10	Net Profit /Loss attributable to											
	a) Controlling Interest											
	b) Non-controlling Interest											
10	Paid up equity share capital	1,265.11	1,265.11	1,221.66	1,265.11	1,265.11	1,265.11	1,221.66	1,221.66	1,265.11		
11	(Rs. 10/- per share)											
	Earning Per Share (Rs.)											
	Basic	3.49	3.25	2.94	12.04	3.12	3.03	2.94	2.94	11.82		
	Diluted	3.49	3.25	2.94	12.04	3.12	3.03	2.94	2.94	11.82		

NOTES :

- 1 The Un-audited financial results for the quarter ended have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 8 August 2023
- 2 This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules,2015 (Ind AS) prescribed under Section 133 of the Companies Act,2013 and other recognised accounting practices and policies to the extent applicable.
- 3 The company operates only in one business segment , viz. Pharmaceuticals formulations, hence segment reporting is not applicable
- 4 The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 -"Earning per Share"
- 5 The results are not comparable on quarterly or yearly basis as company is regularly incurring capex and filling dossiers with regulatory authorities.
- 6 Limited review report has been carried out by the Statutory Auditors for the above period.
- 7 The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

For & on behalf of Board of Directors
Medicamen Biotech Limited



R. Bishnoi

(Rahul Bishnoi)
Chairman

Place : New Delhi

Dated : 08.08.2023